Open Access

Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model

  • Authors:
    • Nitin Telang
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/wasj.2019.9
  • Pages: 86-91
  • Copyright: © Telang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human epidermal growth factor receptor‑2 (HER‑2) expression in the presence or absence of hormone receptors dictates HER‑2‑targeted therapy with or without endocrine therapy. These treatment options lead to long‑term systemic toxicity, multi‑drug resistance and the emergence of therapy‑resistant cancer stem cells. These limitations emphasize the need for the development of reliable model systems with which to evaluate stem cell signaling molecules as testable targets for stem cell therapy, and to identify less toxic testable alternatives for therapeutic resistance. In this study, with the aim of identifying such a system, HER‑2‑positive tumorigenic 184‑B5/HER cells were used as a model of HER‑2‑enriched breast cancer. The epidermal growth factor receptor (EGFR)/HER‑2 specific small molecule inhibitor, lapatinib (LAP), was used to select the drug resistant phenotype. Vitamin A derivative, all trans‑retinoic acid (ATRA), and rosemary terpenoid carnosol (CSOL) represented the test agents. The LAP‑resistant (LAP‑R) phenotype exhibited an upregulated expression of select stem cell specific markers, including tumor spheroids, CD44, NANOG and Oct‑4. These data provide evidence for the effective development of a LAP‑R cancer stem cell model. ATRA and CSOL inhibited the expression of stem cell‑specific markers in the LAP‑R phenotype, suggesting that natural products may possess stem cell targeted therapeutic efficacy via the downregulation of select signaling molecules that are functional in cancer stem cells. On the whole, the findings of this study validate a cancer stem cell model which is able to identify natural products as testable alternatives for the treatment of therapy‑resistant HER‑2‑enriched breast cancer.

References

1 

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI View Article : Google Scholar

2 

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 353:1673–1684. 2005.PubMed/NCBI View Article : Google Scholar

3 

Baselga J and Swain SM: Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009.PubMed/NCBI View Article : Google Scholar

4 

Johnston SRD and Dowsett M: Aromatase inhibitors for breast cancer: Lessons from the laboratory. Nat Rev Cancer. 3:821–831. 2003.PubMed/NCBI View Article : Google Scholar

5 

Musgrove EA and Sutherland RL: Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 9:631–643. 2009.PubMed/NCBI View Article : Google Scholar

6 

Lee KW, Bode AM and Dong Z: Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer. 11:211–218. 2011.PubMed/NCBI View Article : Google Scholar

7 

Ye I, Jia Y, Ji KE, Sanders AJ, Xue K, Ji J, Mason MD and Jiang WG: Traditional Chinese medicine in the prevention and treatment of breast cancer and cancer metastasis. Oncol Lett. 10:1240–1250. 2015.PubMed/NCBI View Article : Google Scholar

8 

Telang NT, Katdare M, Bradlow HL, Osborne MP and Fishman J: Inhibition of proliferation and modulation of estradiol metabolism: Novel mechanisms for breast cancer prevention by the phytochemical indole-3-carbinol. Proc Soc Exp Biol Med. 216:246–252. 1997.PubMed/NCBI

9 

Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem. 273:21875–21882. 1998.PubMed/NCBI View Article : Google Scholar

10 

Katdare M, Osborne M and Telang NT: Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells. Int J Oncol. 21:809–815. 2002.PubMed/NCBI View Article : Google Scholar

11 

Katdare M, Osborne MP and Telang NT: Novel cell culture models for prevention of human breast cancer (Review). Int J Oncol. 22:509–515. 2003.PubMed/NCBI View Article : Google Scholar

12 

Jinno H, Steiner MG, Nason-Burchenal K, Osborne MP and Telang NT: Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells. Int J Oncol. 21:127–134. 2002.PubMed/NCBI View Article : Google Scholar

13 

Subbaramaiah K, Cole PA and Dannenberg AJ: Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 62:2522–2530. 2002.PubMed/NCBI

14 

Subbaramaiah K, Michaluart P, Sporn MB and Dannenberg AJ: Ursolic acid inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Cancer Res. 60:2399–2404. 2000.PubMed/NCBI

15 

Telang N: Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer. Oncol Lett. 16:5489–5497. 2018.PubMed/NCBI View Article : Google Scholar

16 

Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.PubMed/NCBI View Article : Google Scholar

17 

Patel SA, Ndabahaliye A, Lim PK, Milton R and Rameshwar P: Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (Dove Med Press). 2:1–11. 2010.PubMed/NCBI

18 

Yang F, Zhang J and Yang H: OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2+ breast cancer patients. OncoTargets Ther. 11:7873–7881. 2018.PubMed/NCBI View Article : Google Scholar

19 

Telang N: Putative cancer-initiating stem cells in cell culture models for molecular subtypes of clinical breast cancer. Oncol Lett. 10:3840–3846. 2015.PubMed/NCBI View Article : Google Scholar

20 

Telang N: Growth inhibitory efficacy of natural products in a model for triple negative molecular subtype of clinical breast cancer. Biomed Rep. 7:199–204. 2017.PubMed/NCBI View Article : Google Scholar

21 

Telang N: Stem cell targeted therapeutic approaches for molecular subtypes of clinical breast cancer. World Acad Sci J. 1:20–24. 2019. View Article : Google Scholar

22 

Zhai YF, Beittenmiller H, Wang B, Gould MN, Oakley C, Esselman WJ and Welsch CW: Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene. Cancer Res. 53:2272–2278. 1993.PubMed/NCBI

23 

Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ and Gilmer TM: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 1:85–94. 2001.PubMed/NCBI

24 

Nahta R, Yuan LXH, Du Y and Esteva FJ: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther. 6:667–674. 2007.PubMed/NCBI View Article : Google Scholar

25 

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131:861–872. 2007.PubMed/NCBI View Article : Google Scholar

26 

Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, Lerou PH, Lensch MW and Daley GQ: Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 451:141–146. 2008.PubMed/NCBI View Article : Google Scholar

27 

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin II and Thomson JA: Human induced pluripotent stem cells free of vector and transgene sequences. Science. 324:797–801. 2009.PubMed/NCBI View Article : Google Scholar

28 

Nguyen PH, Giraud J, Staedel C, Chambonnier L, Dubus P, Chevret E, Bœuf H, Gauthereau X, Rousseau B, Fevre M, et al: All-trans retinoic acid targets gastric cancer stem cells and inhibits patient-derived gastric carcinoma tumor growth. Oncogene. 35:5619–5628. 2016.PubMed/NCBI View Article : Google Scholar

29 

Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, Büchler MW, Salnikov AV and Herr I, Sainikov AV and Herr I: Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 19:188–195. 2011.PubMed/NCBI View Article : Google Scholar

30 

Zhou W, Kallifatidis G, Baumann B, Rausch V, Mattern J, Gladkich J, Giese N, Moldenhauer G, Wirth T, Büchler MW and Herr I: Dietary polyphenol quercetin targets pancreatic cancer stem cells. Int J Oncol. 37:551–561. 2010.PubMed/NCBI View Article : Google Scholar

31 

Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, et al: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 70:5004–5013. 2010.PubMed/NCBI View Article : Google Scholar

32 

Castro NP, Rangel MC, Merchant AS, MacKinnon G, Cuttitta F, Salomon DA and Kim YS: Sulforaphane suppresses the growth of triple negative breast cancer stem-like cells in vitro and in vivo. Cancer Prev Res (Phila). 12:147–158. 2019.PubMed/NCBI View Article : Google Scholar

33 

Kim SH and Singh SV: Role of Kruppel-like factor 4-p21CIP1 axis in breast cancer stem-like cell inhibition by benzyl isothiocyanate. Cancer Prev Res (Phila). 12:125–134. 2019.PubMed/NCBI View Article : Google Scholar

34 

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, et al: A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anti-cancer compounds. Cell. 167:260–274, e22. 2016.PubMed/NCBI View Article : Google Scholar

35 

Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber E, Balgobind AV, Wind K, Gracanin A, et al: A living biobank of breast cancer organoids captures disease heterogeneity. Cell. 172:373–386, e10. 2018.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

March 2019
Volume 1 Issue 2

Print ISSN: 2632-2900
Online ISSN:2632-2919

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Telang, N. (2019). Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model . World Academy of Sciences Journal, 1, 86-91. https://doi.org/10.3892/wasj.2019.9
MLA
Telang, N."Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model ". World Academy of Sciences Journal 1.2 (2019): 86-91.
Chicago
Telang, N."Targeting drug resistant stem cells in a human epidermal growth factor receptor‑2‑enriched breast cancer model ". World Academy of Sciences Journal 1, no. 2 (2019): 86-91. https://doi.org/10.3892/wasj.2019.9